Efficacy and safety of SAR407899A in patients with painful diabetic neuropathy. A 28-day, randomized, double-blind, placebo-controlled, parallel-group study.

Trial Profile

Efficacy and safety of SAR407899A in patients with painful diabetic neuropathy. A 28-day, randomized, double-blind, placebo-controlled, parallel-group study.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Sep 2014

At a glance

  • Drugs SAR 407899 (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 21 Jul 2012 Planned end date changed from 26 Aug 2010 to 11 Sep 2010 as reported by European Clinical Trials Database.
    • 14 Jul 2012 Actual initiation date changed from 26 Nov 2009 to 11 Dec 2009, as reported by European Clinical Trials Database.
    • 21 Apr 2012 Additional location (Germany) added as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top